Zai Lab wins China reimbursement listing for KarXT and VYVGART Hytrulo in 2026
Zai Lab said five of its medicines were included in China's 2026 National Reimbursement Drug List, including two first-time listings, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Zai Lab reported, according to TradingView, that five of its commercial medicines in China have been added to the country's 2026 National Reimbursement Drug List. Two products were listed for the first time: VYVGART Hytrulo for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies, and KarXT for adult schizophrenia.
Three products received renewals: NUZYRA, QINLOCK and AUGTYRO, which keep their access for oncology and infectious disease patients. The new list takes effect on January 1, 2027.
why it matters
Inclusion on the national reimbursement list typically widens patient access and can support sales volumes in China. For Zai Lab shares this is a modestly positive signal, though the effect on the broader market is limited.
market impact
Zai Lab: wider patient access to its drugs in China supports sales prospects
tags
instruments
sources
- Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products — TradingView, 14 November 2026 at 03:26 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗